Laboratory Monitoring for Post-PCI Stroke Patient with Multiple Comorbidities

Initial Essential Laboratory Tests

The American Heart Association recommends obtaining a comprehensive laboratory panel, including complete blood count, coagulation studies, comprehensive metabolic panel with electrolytes and renal function, cardiac biomarkers, blood glucose, and oxygen saturation, to detect hemorrhagic transformation, monitor kidney function deterioration, and prevent secondary complications in post-PCI stroke patients with multiple comorbidities 1, 2, 3
Electrolytes, such as sodium, potassium, chloride, and bicarbonate, should be monitored to detect metabolic derangements that can worsen neurological status and identify complications from AKI 1, 2
Blood glucose should be monitored to rule out hypoglycemia and hyperglycemia, which can worsen stroke outcomes 3, 4
Troponin should be measured to identify concurrent myocardial infarction or cardiac injury, particularly relevant given recent PCI 1, 2, 3
A 12-lead ECG should be performed to detect arrhythmias, structural heart disease, or evidence of myocardial infarction 1, 2

The American College of Cardiology recommends daily monitoring of serum creatinine to track AKI progression or recovery 5
Electrolytes should be monitored daily to detect and correct imbalances that may worsen with AKI or diuretic therapy for hypertension 5
Blood glucose should be monitored multiple times daily to detect hypoglycemia or hyperglycemia 3
Coagulation studies, such as PT/INR and aPTT, should be monitored every 2-3 days to ensure therapeutic range without excessive bleeding risk 3, 4

The American Heart Association recommends considering transfusion for hemoglobin levels <7 g/dL, although current thresholds may be inadequate for stroke patients 4
INR >1.7 is associated with increased hemorrhagic transformation risk in stroke patients 4
Platelet count <100,000/mm³ is a contraindication for thrombolytic therapy and increases bleeding risk 4
aPTT >1.5 times upper limit of normal requires adjustment of anticoagulation therapy 4
Creatinine increase ≥0.3 mg/dL in 48 hours defines AKI Stage 1, requiring nephrotoxin discontinuation and volume status assessment 5
Urine output <0.5 mL/kg/h for >6 hours is an alternative AKI diagnostic criterion 5
Stage 3 AKI requires nephrology consultation 5
Glucose <70 mg/dL or >180 mg/dL requires urgent correction to prevent hypoglycemia or hyperglycemia-related complications 3
Severe electrolyte abnormalities, such as sodium <125 or >155 mEq/L, potassium <3.0 or >5.5 mEq/L, require urgent correction 5

The American College of Cardiology recommends obtaining a lipid profile during hospitalization for secondary stroke prevention planning 1, 2
Hemoglobin A1c or oral glucose tolerance test should be performed to screen for diabetes as a stroke risk factor 1, 2
TIMP-2 and IGFBP7 can predict progression to severe AKI 5

The American Heart Association recommends not delaying urgent interventions waiting for non-essential laboratory results, as time is critical in stroke management 4
Recognizing the synergistic risk of combined pneumonia and AKI is crucial, as it is associated with high mortality and major adverse kidney events rate 4
Monitoring for hemorrhagic transformation is mandatory in post-PCI patients receiving dual antiplatelet therapy, increasing bleeding risk in the setting of acute stroke 3, 4
Assessing volume status carefully is essential in AKI management to distinguish prerenal from intrinsic renal injury 5
Discontinuing nephrotoxins immediately is crucial to prevent further renal injury 5